Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Location : Boston Convention & Exhibition Center, Boston, MA ...

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

Genes behind the diseaseDo you feel exhausted when it is hot outside? It could be an early sign of the debilitating neurological disease multiple sclerosis, an NHS GP has warned.According to Dr Asif ...

ON THIS PAGEHome Modifications That Can HelpHome Modifications Are One Part of Care for SPMSMobility complications are often the first sign that relapsing-remitting multiple sclerosis (RRMS) is ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod.